Skip to content
TrialScanner

NCT01455389

TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer

Phase 1/Phase 2TerminatedGNPXLead

Registry record

Lead sponsor
Genprex, Inc.
Conditions
Lung Cancer
Primary completion
Oct 27, 2016Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT01455389 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT01455389: TUSC2-nanoparticles and... | TrialScanner